Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA.
Technol Cancer Res Treat. 2012 Jun;11(3):267-78. doi: 10.7785/tcrt.2012.500295. Epub 2012 Mar 15.
The increasing efficacy of pediatric cancer therapy over the past four decades has produced many long-term survivors that now struggle with serious treatment related morbidities affecting their quality of life. Radiation therapy is responsible for a significant proportion of these late effects, but a relatively new and emerging modality, proton radiotherapy hold great promise to drastically reduce these treatment related late effects in long term survivors by sparing dose to normal tissues. Dosimetric studies of proton radiotherapy compared with best available photon based treatment show significant dose sparing to developing normal tissues. Furthermore, clinical data are now emerging that begin to quantify the benefit in decreased late treatment effects while maintaining excellent cancer control rates.
在过去的四十年中,儿科癌症治疗的效果不断提高,产生了许多长期生存者,他们现在正在与严重的治疗相关的疾病作斗争,这些疾病影响了他们的生活质量。放射治疗是这些晚期效应的一个重要原因,但一种相对较新的、新兴的治疗模式——质子放射治疗,通过对正常组织的剂量保护,为大幅度减少长期生存者的这些治疗相关的晚期效应带来了巨大的希望。与最佳的光子治疗相比,质子放射治疗的剂量学研究显示对发育中的正常组织有显著的剂量保护。此外,现在开始出现临床数据,开始量化减少晚期治疗效果的益处,同时保持出色的癌症控制率。